David Johnston
Keine laufenden Positionen mehr
Profil
Dr. David Johnston ist Executive VP-Global Clinical Development bei PPD, Inc. Dr. Johnston war zuvor als Senior Vice President bei Laboratory Corp. of America Holdings beschäftigt. Er war auch im Vorstand von Locus Biosciences, Inc. Er erhielt seinen Bachelor-Abschluss von der University of North Carolina in Greensboro und einen Doktortitel von der UNC School of Medicine.
Ehemalige bekannte Positionen von David Johnston
| Unternehmen | Position | Ende |
|---|---|---|
| PPD, INC. | President | 01.10.2023 |
| THERMO FISHER SCIENTIFIC | Chief Tech/Sci/R&D Officer | - |
Locus Biosciences, Inc.
 Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Director/Board Member | - |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | Corporate Officer/Principal | - |
Ausbildung von David Johnston
| The University of North Carolina at Greensboro | Undergraduate Degree |
| UNC School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| LABORATORY CORPORATION OF AMERICA HOLDINGS | Health Services |
| THERMO FISHER SCIENTIFIC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Locus Biosciences, Inc.
Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Technology Services |
PPD, Inc.
 PPD, Inc. Miscellaneous Commercial ServicesCommercial Services PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. It operates through the Clinical Development Services and Laboratory Services segments. The Clinical Development Services segment focuses in early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment comprises of bioanalytical, vaccine sciences, GMP, central lab and biomarker testing. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC. | Commercial Services |
